The European Medicines Agency adds a psychedelic compound for the first time to its support scheme for priority drugs addressing unmet medical needs.
The European Medicines Agency (EMA) has for the first time included a psychedelic treatment in its PRIME (Priority Medicines) scheme, a significant step for the field in Europe. The compound, bretisilocin, is being developed for the treatment of major depressive disorder and is currently in phase 2 of clinical trials.
The PRIME scheme is designed to support the development of medicines that address unmet medical needs. It offers early and continuous interaction with regulators, as well as stronger use of regulatory tools, including the possibility of accelerated assessment at later stages. Although it is not an approval pathway, it is considered the closest European equivalent to the US FDA’s Breakthrough Therapy designation.
Until now, psychiatry has had a limited presence within PRIME compared with other therapeutic areas such as oncology. In parallel, the United States has granted several such designations to psychedelic treatments, which underlines the difference in pace between the two regulatory environments.
What is bretisilocin?
Bretisilocin was originally developed by Gilgamesh Pharmaceuticals and now belongs to AbbVie. It is described as a serotonin 5-HT2A receptor agonist and serotonin releaser, with a short-acting psychoactive experience. Its inclusion in PRIME indicates that the preliminary data available were judged promising enough to justify greater regulatory support.
The decision comes at a time when mental health and unmet medical needs are gaining weight in the review of European pharmaceutical legislation. In this process, organisations such as PAREA have argued for greater attention to innovation in mental health.
The EMA has also recently encouraged developers of psychedelic therapies to engage early with European regulators and to use tools such as PRIME, pointing to the importance of aligning development strategies with regulatory expectations from the early stages.
Although inclusion in PRIME does not guarantee the treatment’s approval, it does mark a change in the relationship between European regulators and the development of psychedelic therapies. More advanced clinical data will still be needed, as well as future regulatory and access decisions at national level. All the same, this move could point to greater openness in Europe towards this kind of innovation in mental health.



